Ghassan Ghorayeb, MD
Ophthalmology · Clarksburg, WVNPI 1962690958
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,755 of the $3,438 with a category attached, or 80.2%. Regeneron accounts for 80.2% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $2,878, more than ten times the $29 reported in 2020.
Across 13 payments — averaging $264.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$3K
- Regeneron Healthcare Solutions, Inc.$268
- Genentech USA, Inc.$124
- Immunocore Limited$122
- Apellis Pharmaceuticals, Inc.$85
- Mallinckrodt Hospital Products Inc.$44
- plus $39 from 2 others
Across 191 payments — averaging $4895.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$384K
- Genentech, Inc.$340K
- Bayer$90K
- Novartis$71K
- AbbVie$24K
- Mylan Technologies Inc.$9K
- plus $16K from 3 others
What the payments were for
- Travel & lodging$2,75580%
- Food & beverage$67019%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 3 | $2,755 |
| Regeneron Healthcare Solutions, Inc. | 4 | $268 |
| Genentech USA, Inc. | 1 | $124 |
| Immunocore Limited | 1 | $122 |
| Apellis Pharmaceuticals, Inc. | 1 | $85 |
| Mallinckrodt Hospital Products Inc. | 1 | $44 |
| Eyepoint US, Inc. | 1 | $22 |
| Alcon | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,438 in reported general payments places this provider in the 75th percentile of 85 ophthalmology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 82 | $3,429 |
| Bromfenac Sodium | 11 | $1,381 |
| MoxifloxacinMoxifloxacin Hcl | 72 | $785 |
| Ketorolac Tromethamine | 29 | $718 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 24 | $311 |
| Cyclopentolate Hcl | 35 | $252 |
| Latanoprost | 14 | $212 |
| Brimonidine Tartrate | 11 | $120 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Clarksburg
- Anthony RealiniMorgantown$410K
- Vishal VermaHuntington$159K
- Joseph SinclairCharleston$9K
- Brian GriffithCharleston$9K
- Stephen CassisMadison$8K
- Jason LudlowCharleston$8K
- Brian McMillanMorgantown$8K
- David GeorgeParkersburg$7K
- Lawrence MinardiCharleston$7K
- Taoufik SadatHinton$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.